RESEARCH MONOGRAPH · KDC-MN-124

P21 (Cerebrolysin-derived peptide)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

54/100

CNTF-derived neurogenic fragment with intriguing rodent data and basically no human RCT base

P21 is a small peptide derived from the active region of CNTF (ciliary neurotrophic factor), specifically associated with the Khalid Iqbal lab's work at New York State Institute for Basic Research in Developmental Disabilities. The starting point was the observation that Cerebrolysin (a porcine brain hydrolysate used as a neurorestorative drug in parts of Europe and Asia) had pro-neurogenic effects, and the Iqbal group worked to identify the active fragments. P21 emerged from that program as a small synthetic peptide that mimicked some of the neurogenesis-inducing activity in mouse models.

The preclinical data, mostly from the Iqbal lab and collaborators, has shown effects on hippocampal neurogenesis, cognitive endpoints in aged and disease-model mice (Alzheimer's models, Down syndrome models, traumatic brain injury models), and a plausible mechanism through CNTF receptor pathway activation and downstream JAK-STAT and BDNF signaling. The Bolognin 2014 and Kazim 2014 papers in particular established the basic phenotypic effects in different mouse models.

The translation gap is enormous. P21 has essentially no published human RCT data, no commercial pharmaceutical development that's reached clinical trials in the publicly visible literature, and the entire human-relevance argument relies on extrapolation from Cerebrolysin's clinical use (which is itself controversial outside of certain European and Asian regulatory environments) and from preclinical rodent work. As a research peptide it sits firmly in the "interesting hypothesis, unproven in humans" category.

The peptide-research community has picked up P21 in recent years partly because of the CNTF connection and partly because of the modest preclinical Alzheimer's model data. The supplement-grade peptide market has begun offering it, which is concerning because the synthesis is more complex than typical short peptides and the quality variance is real.

What we like: legitimate scientific pedigree from the Iqbal lab, plausible mechanism through CNTF pathway, real preclinical neurogenesis data in multiple disease models. The hypothesis is well-formed even if the human translation is unproven.

What we dont like is the gap between the rodent data and the human research-peptide marketing. P21 has not been validated in any human trial we can find in the indexed literature, and treating it as a clinical-application compound is far ahead of where the science is.

Sourcing: P21 from reputable peptide suppliers should run HPLC 98%+ purity. The synthesis is moderately complex and quality variance between suppliers is real. Reconstitution is standard, storage is normal for short peptides, the molecule is reasonably stable.

Interesting research tool, very far from clinical readiness, treat the marketing skeptically. The rodent biology is real, the human extrapolation is not.

Evidence: 30
Mechanism: 60
Reliability: 45
Safety: 65
Sourcing: 70
Value: 55
Signal: 50
Staying power: 55

Plain-language summary Intrigue 65 / 100

P21 is a synthetic peptide derived from ciliary neurotrophic factor (CNTF) developed for neuroprotection and neurogenesis. Used in research for memory and Alzheimer disease investigations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

CNTF-derived neurogenic peptide

A short peptide derived from a cerebrolysin fraction with documented hippocampal neurogenesis activity in animal models.

Abstract

P21 is a peptide of the sequence Ala-Asp-Asn-Phe-Val-Phe-Lys derived from the active fraction of cerebrolysin (or related neurotrophic preparations) and identified by Khalid Iqbal's group at the New York State Institute for Basic Research. The compound stimulates neurogenesis in the dentate gyrus through a CNTF-receptor-related mechanism, producing dose-dependent improvements in spatial learning and memory in rodent models of cognitive aging and Alzheimer disease pathology. The compound has not been advanced to human clinical trials. Pharmacokinetics are poorly characterized in humans. The compound is sold as a research peptide; reported research dose ranges in the literature parallel the cerebrolysin range scaled to peptide content.

Mechanism of action

CNTF-receptor-related neurogenesis stimulant in dentate gyrus.

Reported research dose ranges

Sparse human data; reported rodent research doses approximately 40 nmol/kg.

References

Iqbal K, et al. Identification of a peptide P21 with neurogenic activity. J Alzheimers Dis 2012.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-124

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

P21 (Cerebrolysin-derived peptide)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs